
Opinion|Videos|August 15, 2023
Triplet Regimens for First-Line Advanced Renal Cell Carcinoma
Author(s)Rana R. McKay, MD
Discussion on triplet therapy regimens in advanced RCC and how progressing therapeutic studies can impact its future use.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5








































